Back to search

National and Kapodistrian University of Athens

Μελέτη των μηχανισμών διαταραχής κάθαρσης αποπτωτικών και νευρωτικών κυττάρων στο Σύνδρομο Sjogren

Abstract

dc:description

Primary Sjögren’s syndrome (SS) is a relatively common autoimmune disorder that is primarily characterized by chronic lymphoepithelial inflammation in the exocrine glands, mainly the salivary and lachrymal glands, leading to dryness. SS may extend from disease confined to the exocrine glands (organ-specific exocrinopathy) to various extraglandular manifestations (systemic disease) and the development of non-Hodgkin’s lymphoma (usually of mucosa-associated lymphoid tissue type; MALT-NHL) in 5% of patients. Approximately one-third of patients manifest clinico-laboratory features that represent high-risk prognostic factors for lymphoma development (type-I disease; as opposed to type-II disease, i.e. without adverse prognostic factors). Although the aetiopathogenesis of the disease remains unclear, evidence indicates the contribution of both innate and adaptive immunity in inflammatory reactions. In this PhD dissertation, we sought to investigate the innate immune responses elicited by tissue injury in SS patients.Apoptosis represents a major mechanism of programmed cell death that is essential for the regulation of tissue growth and homeostasis. Normally, cells dying by apoptosis undergo specific changes that target them for rapid clearance by professional phagocytes, such as macrophages. Typically, this process leads to the active production of anti-inflammatory mediators by phagocytes and thus facilitates the “immunologically silent” removal of apoptotic cells. The prompt elimination of apoptotic cells (also termed “efferocytosis”) is a very crucial biological process, since lingering apoptotic cells eventually proceed to the state of “late apoptosis” or “secondary necrosis” wherein they may contribute to inflammatory reactions via the release of immunogenic intracellular components, including modified autoantigens and “danger signals”. In fact, apoptosis and efferocytosis act in concert to regulate various processes, such as embryogenesis, tissue homeostasis, tolerance the elimination of damaged cells, and the resolution of inflammation.The occurrence of defective efferocytosis in certain inflammatory diseases is thought to have pathogenetic significance, based on the pro-inflammatory potential of secondary necrotic cells. Among them, systemic lupus erythematosus (SLE) is regarded as the archetypical disease model where the impaired clearance of apoptotic cells by macrophages represents a possible mechanism for the development of chronic autoimmune reactions and organ damage. Given the similarities (serological, immunogenetical and clinical) between SLE and SS, the important role of apoptosis in the pathogenesis of SS and the involvement of macrophages in the development of lymphoepithelial lesions of SS, the aim of current thesis was the investigation of the ability of SS patients’ macrophages for phagocytosis of apoptotic cells and of necrotic material. Compared to healthy blood donors (HBD), approximately half of SS and SLE patients studied (but not RA) were found to manifest significantly reduced phagocytosis of apoptotic cells by blood-borne phagocytes (ApoCell-phagocytosis). We showed that this aberration owed to the high levels of antibodies against apoptotic cells, which were present in the sera of SS and SLE patients studied (but not of RA) and, as revealed in functional experiments, they were able to inhibit the normal phagocytosis of apoptotic cells. Purified serum IgG from SS and SLE patients showed direct inhibition of ApoCell-phagocytosis by healthy monocytes and this correlated linearly with the levels of antibodies against apoptotic cells in those preparations, as well as with the presence of C3 and C4 hypocomplementemia in the respective patients. Moreover, dysfunction of phagocytes may be also present in several SS and SLE patients, as evidenced by deficient capacity of differentiated MDM for phagocytosis of apoptotic cells and microbeads. Our findings indicate that, alike in SLE, impaired efferocytosis may be also a feature of pathogenetic importance for SS.Previous experimental data have suggested that SLE patients exhibit not only defective efferocytosis, but also reduced serum mediated degradation of necrotic cell debris and increased phagocytic uptake of necrotic cells. In fact, these aberrations are thought to be involved in the pathogenesis of chronic inflammatory reactions that characterize this disease. Herein, primary Sjogren's syndrome (SS) patients were investigated for the first time for the capacity of their sera to degrade secondary necrotic cell remnants (SNEC) and DNA (endonuclease DNase1 activity), as well as for uptake of SNEC by blood-borne phagocytes. Firstly, we have shown that patients with SS exhibit significantly increased amounts of nucleosomes and circulating cell-free DNA (cf-DNA) in the peripheral blood. Compared to HBD, the sera from SS and SLE patients studied (but not RA) were found to exhibit significantly impaired capacity for degradation of SNEC and deficient DNase1 activity that correlated inversely with disease activity indices of SS and SLE. The sera of SS and SLE patients (but not of RA) with decreased DNase1 activity induced significant SNEC-phagocytosis by healthy monocytes. In line with this, the inhibition of DNase1 in HBD sera by G-actin was found to lead to significantly diminished SNEC degradation and increased SNEC uptake by healthy phagocytes, supporting the important physiologic role of serum DNase1 in the prevention of SNEC-phagocytosis. Purified serum IgG preparations from SS and SLE patients manifested increased binding to SNEC and were able to enhance significantly the engulfment of SNEC by healthy phagocytes. The latter was shown to occur both directly (under serum-free conditions) and via the prevention of physiologic degradation of SNEC by serum, most likely due to their “shielding” against endonuclease digestion. In all, our data indicate that upon cell necrosis, the immune system of SS and SLE patients may be overly exposed to the necrotic debris, a fact that probably holds a key role in the pathogenesis of inflammatory and autoimmune reactions observed in these disorders.Our previous data have indicated that SS patients manifest a) aberrant clearance of apoptotic cells by phagocytes and b) impaired serum DNaseI-mediated degradation of necrotic cell remnants. These aberrations were shown to be associated with the occurrence of increased amounts of circulating nucleosomes and cell-free DNA (cf-DNA) in the blood. In this context, we sought to investigate the possible occurrence of extranuclear DNA accumulations in the peripheral blood monocytes and the salivary gland tissues of SS patients, and whether such accumulation leads to the activation of the inflammasomes. Inflammasomes are a group of multimeric protein complexes that represent a major innate immune response platform, whose activation leads to the activation of caspase 1, to the production of the pro-inflammatory cytokines IL-1β and IL-18 and finally to pyroptotic cell death. Various pathogen-derived and endogenous molecules, including nucleic acids that are released following tissue injury, have been shown to induce inflammasome activation.On this basis, we herein sought to investigate the status of inflammasome activation in sera, PBMC, circulating monocytes and the minor salivary gland specimens derived from various disease severity subgroups of SS patients (including patients with mild disease, patients in high risk for lymphoma development and patients with NHL). SS-patients at high risk for lymphoma and those with established lymphoma were found to display high serum cf-DNA levels, substantial extranuclear DNA accumulations in PBMC and the salivary gland tissue, a unique NLRP3-inflammasome gene signature in the PBMC, and significantly increased IL-18 and ASC levels in serum. In these patients, the circulating monocytes manifested NLRP3 inflammasome activation and increased response to NLRP3-stimuli, whereas salivary gland-infiltrating macrophages exhibited signs of NLRP3 activation and pyroptosis. Cell-free nucleic acids isolated from patients’ sera competently primed the activation of both NLRP3- and AIM2-inflammasome in healthy monocytes.Normally, the inflammagenic accumulation of DNA is prevented by deoxyribonucleases acting in the serum (DNaseI), the cytosol (TREX1/DNaseIII) and the lysosomes (DNaseII). We showed that SS patients are characterized by decreased serum activity of DNaseI, as well as by reduced expression of DNaseII in the peripheral blood monocytes. These aberrations were inversely correlated with indices of inflammasome activation in the peripheral blood of SS patients. In addition, the DNaseII gene-silencing in healthy monocytes was found to lead to cytoplasmic DNA deposition and activation of inflammasome-related genes and of caspase1. Conclusively, severe SS is characterized by systemic NLRP3-inflammasome activation associated with widespread extranuclear accumulations of inflammagenic DNA, correlating with impaired DNA degradation. These findings can provide novel biomarkers and new therapeutic targets for the management of SS-patients with adverse outcomes.Several lines of evidence presented previously from our group indicate that the ductal salivary gland epithelial cells of SS patients have an important role in the development of systemic inflammatory reactions, as well as those seen in salivary gland (SG) tissues. Using a well-established system for the long-term cultivation of long-term cultured non-neoplastic ductal salivary gland epithelial cell lines (SGEC) and the parallel analyses of cells derived from SS patients (SS-SGEC) and those from non-SS disease controls, we have previously provided evidence of an intrinsic activation process that operates in SS epithelia. In this dissertation, we investigated the expression and function of the peroxisome proliferator-activated receptor gamma (PPARγ) in epithelial cells of patients with SS. PPARγ is a nuclear transcription factor that mediates important anti-inflammatory activities in epithelial cells. Herein, the comparative analysis of SG biopsies from SS patients and controls revealed constitutively reduced PPARγ protein expression in SS patients that correlated with the severity of lymphocytic infiltrations. Moreover, analysis of SGEC lines revealed that the gene and protein expression, the transcriptional activity and the anti-inflammatory function of PPARγ are constitutively reduced in the ductal epithelia of SS patients. Diminished PPARγ activity in the SGEC of SS patients, was associated with cell-autonomously activated NF-κB and IL-1β pathways, as well as the existence of severe disease manifestations. In addition, the treatment of control SGEC lines with PPARγ agonists was shown to diminish the NF-κB activation and apoptosis induced by proinflammatory agents. Overall, our findings suggest that the intracellular anti-inflammatory factor PPARγ exhibits constitutively decreased expression in the salivary gland epithelium of SS patients with severe lymphocytic infiltrates in tissues, as well as in those with the severe clinical manifestations of the disease, presumably through chronic endogenous cellular activation of NF-κB and the autocrine effect of IL-1β produced by these cells. Furthermore, the in-vitro application of PPARγ agonists and pharmacologic inhibitors of IL-1β and NF-κB to SGEC lines of SS patients was found to have significant beneficial effects, such as the restoration of PPARγ functions and the reduction of intrinsic activation of these cell lines, which may advocate the future clinical study of the above agents as therapeutic modalities for SS. Τhe above aberrations are congruent and complementary to the previously identified cell autonomous activation of ductal epithelia in SS patients. Importantly, the results of this study essentially corroborate the key proinflammatory role of the persistently-activated epithelia of SS patients not only in the pathogenesis of lymphoepithelial lesions in the salivary glands, but also in the development of severe systemic disease manifestations, including B-cell lymphoma. In this context, among other, the transcriptome analyses of SS-SGEC lines have revealed constitutive perturbations in several inflammation- and metabolism-related signaling pathways, which in fact were more pronounced in cell lines derived from patients with severe histopathologic lesions. Such cell-autonomous aberrations included the activation of inflammasome pathway, a fact corroborated by the constitutive activation of caspase-1 and high IL-1β production in SS-SGEC lines. In the last paper of this dissertation, we investigated the activation status of inflammasome in epithelial cells of SS patients, as well as the putative triggering factors. The comparative assessment of cultured ductal SGEC lines and salivary gland tissue specimens revealed the occurrence of cell-intrinsic activation of AIM2 inflammasome in the ductal salivary epithelial cells of SS patients. Furthermore, we demonstrate that AIM2 activation in these cells is instigated by excessive cytoplasmic accumulations of damaged DNA, which correlated with the deficient expression and functionality of the intracellular DNase1. Overall, our results provide a mechanistic explanation for the chronic cell autonomous activation, that characterizes salivary gland epithelial cells of patients with SS, which is probably primarily due to the excessive activation of the AIM2 inflammasome instigated by cytoplasmic accumulations of damaged DNA, which in turn are due to a deficient degradation by intracellular DNase I. These findings are likely to indicate new biomarkers for the diagnosis and monitoring of patients with SS, as well as possible new therapeutic targets for the disease.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • vakrakou, aglaia
  • Βακράκου, Αγλαΐα

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45772

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

vakrakou, aglaia; Βακράκου, Αγλαΐα. Μελέτη των μηχανισμών διαταραχής κάθαρσης αποπτωτικών και νευρωτικών κυττάρων στο Σύνδρομο Sjogren. National and Kapodistrian University of Athens, 2019. http://hdl.handle.net/10442/hedi/45772